These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37013676)

  • 21. Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.
    Cuker A; Lal L; Roy A; Elliott C; Carlyle M; Martin C; Haenig J; Viana R
    Ann Hematol; 2022 Sep; 101(9):1915-1924. PubMed ID: 35849155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi-structured interviews.
    Livingston J; Alrajhi Z; Jackson M; McGuire C; Newhook D; Klaassen RJ; Kirby-Allen M
    Br J Haematol; 2023 Feb; 200(4):506-516. PubMed ID: 36345812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China.
    Wang Z; Wang N; Juntao O; Ma J; Dong S; Meng J; Liu J; Chen Z; Cheng X; Wu R
    Br J Haematol; 2024 Mar; 204(3):1017-1023. PubMed ID: 38087811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
    Shinohara K; Kambara N
    Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind study.
    Sheng XY; Liu ZY; Zhao J; Song L; Zhao WM; Zhao X; Cui YM
    Platelets; 2022 Nov; 33(8):1185-1191. PubMed ID: 35549802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM
    Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
    Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
    Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
    J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real-world study in China.
    Cheng X; Wang Z; Dong S; Ma J; Meng J; Wang X; Wu R
    Br J Haematol; 2023 Aug; 202(3):636-644. PubMed ID: 37188335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia.
    Wang X; Bi H; Liu L; Liu Y; Yin L; Yao J; Yu J; Tao W; Wei Y; Li Y; Yin L; Mu H; Du Y; Zhou Z
    Platelets; 2023 Dec; 34(1):2271568. PubMed ID: 37941414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
    Kuter DJ; Allen LF
    Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
    Skopec B; Sninska Z; Tzvetkov N; Ivanushkin V; Björklöf K; Hippenmeyer J; Mihaylov G
    Hematology; 2021 Dec; 26(1):497-502. PubMed ID: 34238136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.